Cargando…

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune checkpoint inhibitors (ICIs) have been widely eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzo, Alessandro, Ricci, Angela Dalia, Di Federico, Alessandro, Frega, Giorgio, Palloni, Andrea, Tavolari, Simona, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718608/ https://www.ncbi.nlm.nih.gov/pubmed/34976841 http://dx.doi.org/10.3389/fonc.2021.803133

Ejemplares similares

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

Hepatocellular Carcinoma in Pakistan: Where do We Stand?
por: Butt, Amna Subhan, et al.
Publicado: (2012)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
por: Hu, Li-Feng, et al.
Publicado: (2021)

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Immune checkpoint inhibitors in ovarian cancer: where do we stand?
por: Leary, Alexandra, et al.
Publicado: (2021)

Where Do We Stand?
Publicado: (1891)

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?
por: Bartolotta, Tommaso Vincenzo, et al.
Publicado: (2019)

Hepatocellular Carcinoma (HCC), Where do we stand? Current situation
por: Hafeez, Muhammad, et al.
Publicado: (2020)

Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Where do we stand with antithrombotic prophylaxis in patients with COVID-19?
por: Ciavarella, Alessandro, et al.
Publicado: (2020)

Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
por: Franzin, Rossana, et al.
Publicado: (2020)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?
por: Lucarelli, Enrico, et al.
Publicado: (2023)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Genetics of Keratoconus: Where Do We Stand?
por: Abu-Amero, Khaled K., et al.
Publicado: (2014)

Cricoid pressure: Where do we stand?
por: Bhatia, Nidhi, et al.
Publicado: (2014)

Combating Malaria: Where do We Stand?
por: Coats, Mamie T
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3b5u044958fr4jmpnfk2gbp94o